|Positive WB detected in||mouse brain tissue, human brain tissue|
|Positive IHC detected in||human kidney tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
55382-1-AP targets PKA C-beta-specific in WB, IHC,ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, rat|
|Host / Isotype||Rabbit / IgG|
|Full Name||protein kinase, cAMP-dependent, catalytic, beta|
|Calculated molecular weight||46 kDa|
|Observed molecular weight||35-37 kDa|
|GenBank accession number||NM_002731|
|Gene ID (NCBI)||5567|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Aliquoting is unnecessary for -20oC storage.|
PRKACB, also named as PKA C-beta, belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family and cAMP subfamily. It mediates cAMP-dependent signaling triggered by receptor binding to GPCRs. PKA activation regulates diverse cellular processes such as cell proliferation, the cell cycle, differentiation and regulation of microtubule dynamics, chromatin condensation and decondensation, nuclear envelope disassembly and reassembly, as well as regulation of intracellular transport mechanisms and ion flux. This antibody is specific to PRKACB.
Total barley maiya alkaloids inhibit prolactin secretion by acting on dopamine D2 receptor and protein kinase A targets.
Label-Free Quantitative Phosphoproteomics Reveals Regulation of Vasodilator-Stimulated Phosphoprotein Upon Stathmin-1 Silencing in a Pair of Isogenic Colorectal Cancer Cell Lines.
Uncaria rhynchophylla ameliorates unpredictable chronic mild stress-induced depression in mice via activating 5-HT1A receptor: Insights from transcriptomics.
Hypericin attenuates nonalcoholic fatty liver disease and abnormal lipid metabolism via the PKA-mediated AMPK signaling pathway in vitro and in vivo.